Cardiovascular disease in rheumatic diseases


Cite item

Full Text

Abstract

The representatives of immunoinflammatory diseases are rheumatic ones, such as primarily rheumatoid arthritis, juvenile idiopathic arthritis, spondyloarthritis, psoriatic arthritis, systemic lupus erythematosus, and other systemic connective diseases, which are characterized by a high risk for untimely death. The high risk of untimely death in these diseases has been found to be associated with the severity of an immunoinflammatory process that gives rise to severe irreversible damage to vital organs and systems and with the development of a wide spectrum of comorbidities (infections, interstitial lung disease, malignant tumors, osteoporotic fractures, etc.). Among them, diseases of the cardiovascular system, which are most commonly caused by the early development and accelerated progression of atherosclerotic coronary lesions, hold a central position. The paper gives the data available in the recent literature on the impact of antirheumatic therapy (disease-modifying antirheumatic drugs and biological agents) on the cardiovascular system.

References

  1. Cooper GS, Bynum MLK, Somers EC. Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering diseases. J Autoimmun. 2009;33:197-207. doi: 10.1016/j.jaut.
  2. McGonagle D, McDermott MF. A Proposed Classification of the Immunological Diseases. PLoS Med. 2006;3:e297. doi: 10.1371/journal.pmed.0030297.
  3. Wang L, Wang F-S, Gershwin ME. Human autoimmune disease: a comprehensive update. J Intern Med. 2015;278:369-395. doi: 10.1111/joim.12395.
  4. Doria A, Zen M, Bettio S et al. Autoinflammation and autoimmunity: Bridging the divide. Autoimm Rev. 2012;12:22-30. doi: 10.1016/j.autrev.2012.07.018.
  5. Pincus T, Gibson KA, Block JA. Premature mortality: a neglected outcome in rheumatic diseases? Arthritis Care Res. 2015;67:1043-1046. doi: 10.1002/acr.22554.
  6. Cutolo M, Kitas GD, van Riel PLCM. Burden of disease in treated rheumatoid arthritis patients: going beyond the joints. Semin Arthritis Rheum. 2014;43:479-488. doi: 10.1016/j.semarthrit.2013.08.004.
  7. Насонов Е.Л., Гордеев А.В., Галушко Е.А. Ревматические заболевания и мультиморбидность. Терапевтический архив. 2015;5:4-9.
  8. Crowson CS, Liao KP, Davis JM et al. Rheumatoid arthritis and cardiovascular disease. Am Heart J. 2013;166:622-628. doi: 10.1016/j.ahj.2013.07.010.
  9. Nurmohamed MT, Heslinga M, Kitas GD. Cardiovascular comorbidity in rheumatic disease. Nat Rev Rheumatol. 2015;11:693-704. doi: 10.1038/nrrheum.2015.112.
  10. Prasad M, Hermann J, Gabriel SE et al. Cardiorheumatology: cardiac involvement in systemic rheumatic diseases. Nat Rev Cardiol. 2015;12:168-176. doi: 10.1038/nrcardio.2014.206.
  11. Smolen JS, Aletaha D, Bijsma JWJ et al. For the T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69:631-637. doi: 10.1136/ard.2009.123919.
  12. Насонов Е.Л., Мазуров В.И., Каратеев Д.Е., Лукина Г.В., Жиляев E.В., Амирджанова В.Н., Муравьев Ю.М., Чичасова Н.В. Проект рекомендаций по лечению ревматоидного артрита Общероссийской общественной организации «Ассоциация ревматологов России-2014 (часть 1). Научно-практическая ревматология. 2014;52:477-494. doi: 10.14412/1995-4484-2014-477-494.
  13. Smolen JS, Landewe R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73:492-509. doi: 10.1136/annrheumdis-2013-204573.
  14. Avina-Zubieta JA, Thomas J, Sadatsafavi M, Lehman AJ, Lacaille D. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis. 2012;71:152401529. doi: 10.1136/annrheumdis-2011-200726.
  15. Ross R. Atherosclerosis — an inflammatory disease. N Engl J Med. 1999;340:115.
  16. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-1695.
  17. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011;473:317-325. doi: 10.1038/nature10146.
  18. Pasceri V, Yeh ET. A tale of two diseases: atherosclerosis and rheumatoid arthritis. Circulation. 1999;100:2124-2126.
  19. Насонов Е.Л. Проблема атеротромбоза в ревматологии. Вестник РАМН. 2003;7:6-10.
  20. Skeoch S, Bruce IN. Atherosclerosis in rheumatoid arthritis: is it all about inflammation? Nat Rev Rheumatol. 2015;11:390-400. doi: 10.1038/nrrheum.2015.40.
  21. Barbarroja N, Perez-Sancherz C, Ouiz-Limon P et al. Anticyclic citrullinsted protein antibodies are implicated in the development of cardiovascular disease in rheumatoid arthritis. Arterioscler Thromb Vasc Biol. 2014;34:2706-2716. doi: 10.1161/ATVBAHA.114.304475
  22. Кондратьева Л.В., Попкова Т.В., Насонов Е.Л. Метаболический синдром при ревматоидном артрите. Научно-практическая ревматология. 2013;51:302-312. doi: 10.14412/1995-4484-2013-1506.
  23. Попкова Т.В., Новикова Д.С., Насонов Е.Л. Атеросклероз при ревматических заболеваниях. В кн.: Генно-инженерные биологические препараты в лечении ревматоидного артрита. Под ред. акад. РАМН Насонова Е.Л. М.: ИМА-пресс; 2013.
  24. Robertson J, Peters MJ, McInnes IB, Sattar N. Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm. Nat Rev Rheumatol. 2013;9:513-523. doi: 10.1038/nrrheum.2013.91.
  25. Myasoedova E, Crowson CS, Kremers HM, Roger VL, Fitz-Gibbon PD, Therneau TM et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis. 2011;70:482-487.
  26. Solomon DH, Reed GW, Kremer JM, Curtis JR, Farkouh ME, Harrold LR et al. Disease activity in rheumatoid arthritis and the risk of cardiovascular events. Arthritis Rheumatol. 2015;67:1449-1455. doi: 10.1002/art.39098.
  27. Nurmohamed MT. Editorial: Treat to Target in Rheumatoid Arthritis: Good for the Joints as Well as the Heart? Arthritis Rheum. 2015;67:1412-1415. doi: 10.1002/art.39096.
  28. Насонов Е.Л. Метотрексат: перспективы применения в ревматологии. М.: Филоматис; 2005.
  29. Генно-инженерные биологические препараты в лечении ревматоидного артрита. Под ред. Насонова Е.Л. М.: ИМА-пресс; 2013.
  30. Siebert S, Tsoukas A, Robertson J, McInnes I. Cytokines as therapeutic targets in rheumatoid arthritis and other inflammatory diseases. Pharmacol Rev. 2015;280-309. doi: 10.1124/pr.114.009639.
  31. Khan R, Spagnoli V, Tarddif J-C, L`Allier PL. Novel anti-inflammatory therapies for treatment of atherosclerosis. Atherosclerosis. 2015;240:497-509. doi: 10.1016/j.atherosclerosis.2015.04.783.
  32. Ridker PM, Lüscher TF. Anti-inflammatory therapies for cardiovascular disease. Eur Heart J. 2014;14(35):1782-1791. doi: 10.1093/eurheartj/ehu203.
  33. Back M, Hansson GK. Anti-inflammatory therapies for atherosclerosis. Nat Rev Cardiol. 2015;12:199-211. doi: 10.1038/nrcardio.2015/5.
  34. Popkova TV, Novikova DS, Gasparyan AY, Nasonov EL. Cardiovascular effects of methotrexate in rheumatoid arthritis. Curr Med Chem. 2015;22:1903-1910.
  35. Micha R, Imamura F, von Ballmoos MV et al. Systemic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol. 2011;108:1362-1370. doi: 10.1016/j.amjcard.2011.06.054.
  36. Roubille C, Richer V, Startino T et al. The effect of tumor necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systemic review and meta-analysis. Ann Rheunm Dis. 2015;74:480-489. doi: 10.1136/annrheumdis-2014-206624.
  37. Wasko MC, Dasgupta A, Hubert H, Fries JF, Ward MM. Propensity-adjustment association of methotrexate with overall survival in rheumatoid arthritis. Arthritis Rheum. 2013;65:334-342. doi: 10.1002/art.37723.
  38. Bulgarelli A, Martins Dias AA, Caramelli B, Maranhao RC. Treatment with methotrexate inhibits atherogenesis in cholesterol-fed rabbits. J Cardiovasc Pharmacol. 2012;59:308-314. doi: 10.1097/FJC.0b013e318241c385.
  39. Насонов ЕЛ. Метотрексат при ревматоидном артрите — 2015: новые факты и идеи. Научно-практическая ревматология. 2015;53:64-76.
  40. Charles-Schoeman C, Lee YY, Grijalva V, Amjadi S, FitzGerald J, Ranganath VK, Taylor M, McMahon M, Paulus HE, Reddy ST. Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis. Ann Rheum Dis. 2012;71(7):1157-1162. doi: 10.1136/annrheumdis-2011-200493.
  41. Erhayiem B, Pavitt S, Baxter P et al. Coronary artery disease evaluation in rheumatoid arthritis (CADERA): study protocol for a randiomized controlled trial. Trials. 2014;15:436.
  42. Barnabe C, Martin BJ, Ghali WA. Systematic review and meta-analysis: anti-tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res. 2011;63:522-529. doi: 10.1002/acr.20371.
  43. Daïen CI, Duny Y, Barnetche T, Daurès JP, Combe B, Morel J. Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis. Ann Rheum Dis. 2012;71:862-868. doi: 10.1136/annrheumdis-2011-201148.
  44. Mann DL, McMurray JJ, Packer M et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation. 2004;109:1594-1602.
  45. Chung ES, Packer M, Lo KH et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003;107:3133-3140.
  46. Удачкина Е.В., Новикова Д.С., Попкова Т.В., Насонов Е.Л. Ревматоидный артрит и атеросклероз: роль интерлейкина-6. Клиническая фармакология и терапия. 2012;21(1):86-92.
  47. Sarwar N, Butterworth AS, Freitag DF, Gregson J, Willeit P, Gorman DN et al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet. 2012;379:1205-1213. doi: 10.1016/S0140-6736(11)61931-4.
  48. Hingorani AD, Casas JP. The interleukin-6 receptor as a target for prevention of coronary heart disease: a Mendelian randomisation analysis. Lancet. 2012;379:1214-1224. doi: 10.1016/S0140-6736(11)61931-4.
  49. Попкова Т.В., Новикова Д.С., Панасюк Е.Ю. и др. Влияние тоцилизумаба на систему транспорта холестерина крови и ранние проявления атеросклероза у больных ревматоидным артритом. Терапевтический архив. 2012;5:9-18.
  50. Удачкина Е.В., Новикова Д.С., Попкова Т.В. и др. Динамика липидных параметров крови у больных ревматоидным артритом на фоне комбинированной терапии тоцилизумабом и метотрексатом в сравнении с монотерапией метотрексатом при 24-недельном наблюдении. Рациональная фармакотерапия в кардиологии. 2015;11(5):510-516.
  51. Rao VU, Pavlov A, Klearman M, Musselman D, Giles JT, Bathon JM, Sattar N, Lee JS. An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy. Arthritis Rheum. 2015;67(2):372-380. doi: 10.1002/art.38920.
  52. Novikova DS, Popkova TV, Nasonov EL. The effect of anti-B-cell therapy on the development of atherosclerosis in patients with rheumatoid arthritis. Cur Pharm Des. 2012;18:1512-1518.
  53. Tsiantoulas D, Sage AP, Mallat Z, Binder JC. Targeting B Cells in Atherosclerosis Closing the Gap From Bench to Bedside. Arteriosclerosis, Thrombosis, and Vascular Biology. 2015;35:296-302. doi: 10.1161/ATVBAHA.114.303569.
  54. Novikova DS, Popkova TV, Lukina GV et al. The effects of rituximab on lipids, arterial stiffness, and carotid intima-media thickness in rheumatoid arthritis. J Korean Med Sci. 2016;31:202-207. doi: 10.3346/jkms.2016.31.2.202.
  55. Новикова Д.С., Попкова Т.В., Герасимова Е.В., Новиков А.А., Александрова Е.Н., Насонов Е.Л. Динамика частоты сердечных сокращений, показателей вариабельности ритма сердца и величины интервала QT у женщин с ревматоидным артритом на фоне лечения ритуксимабом. Научно-практическая ревматология. 2014;3:270-277. doi: 10.14412/1995-4484-2014-270-276.
  56. Насонов Е.Л., Елисеев М.С. Роль интерлейкина-1 в развитии заболеваний человека. Научно-практическая ревматология. 2016;54 (принята к печати).
  57. Dinarello C.A. An expanding role for interleukin-1 blockade from gout to cancer. Molecular Med. 2014;20(Suppl 1):S43-S58. doi: 10.2119/molmed.2014.00232.
  58. Van Tassell BW, Noldo S, Mezzaroma E, Abbate A. Targeting Interleukin-1 in Heart Disease. Circulation. 2013;128:1910-1923 doi: 10.1161/CIRCULATIONAHA.113.003199.
  59. Ridker P M, Thuren T, Zalewski A, Libby P. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J. 2011;162:597-605. doi: 10.1016/j.ahj.2011.06.012.
  60. The Interleukin 1 genetics Consortium. Cardiometabolic effects of genetic upregulation of the interleukin 1 receptor antagonists: a Mendelian randomization analysis. Lancet Diabetes Endocrinol. 2015;3:243-253. doi: 10.1016/S2213-8587(15)00034-0.
  61. Liu S-H, Xie L, Zhang J et al. Gout and risk of myocardial infarction: a systemic review and meta-analysis of cohort studies. PLOS ONE. 2015. doi: 10.1371/journal.pone.0134088.
  62. Dalbeth N, Lauterio TJ, Wolfe HR. Mechanism of action of colhicine in the treatment of gout. Clin Ther. 2014;36:1465-1479. doi: 10.1016/j.clinthera.2014.07.017.
  63. Новикова Д.С., Попкова Т.В., Насонов Е.Л. Снижение кардиоваскулярного риска при ревматоидном артрите: двойная польза статинов. Научно-практическая ревматология. 2010;6:61-72. doi: 10.14412/1995-4484-2010-826.
  64. Xing B, Yin Y-F, Zhao L-D et al. Effect of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor on disease activity in patients with rheumatoid arthritis. Medicine. 2015;94:e572.
  65. Schoenfeld SR, Lu L, Rai SK et al. Statin use and mortality in rheumatoid arthritis: a general population-based study. Ann Rheum Dis. 2015. doi: 10.1136/annrheumdis-2015-207714.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies